A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the impact of these launches will be strengthened by the increasing acceptance of biosimilars as alternatives to more-expensive branded therapies and the novel mechanisms of action that are becoming available. IL-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the sales of current therapies, especially the IL-12/23 therapy ustekinumab. Targeted synthetic DMARDs, particularly JAK inhibitors, will fulfill the need for orally dosed therapies and increasingly capture early-line patient share.
Geographies: United States, EU5, Japan.
Primary research: 24 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other DRG research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2029, segmented by brands / biosimilars.
Emerging therapies: Phase III/PR: 5 drugs; Phase II: 2 drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.